A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 928-932

  Eng, C ^a,d   Kindler, H L ^a   Nattam, S ^b   Ansari, R H ^c   Kasza, K ^a   Wade Oliver, K ^a   Vokes, E E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Fort Wayne Medical Institute   (United States)

^c Northern Indiana Cancer Research Consortium   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Colorectal cancer; Epothilone; Phase II trial

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CREMOPHOR; DEXAMETHASONE; DIPHENHYDRAMINE; EPOTHILONE B; FAMOTIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; IXABEPILONE; NIZATIDINE; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CYTOLOGY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEALTH STATUS; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; SPLEEN CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; TREATMENT FAILURE;

EID: 3442898528     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh236     Document Type: Article

References (19)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
3. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
4. Rothenberg ML, Oza AM, Bigelow RH et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069.
5. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470: M79-M91.
6. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-1437.
7. Griffin D, Wittmann S, Guo F et al. Molecular determinants of epothilone B derivative (BMS 247550) and Apo-2L/TRAIL-induced apoptosis of human ovarian cancer cells. Gynecol Oncol 2003; 89: 37-47.
8. Calvert P, O'Neill V, Twelves C. A phase I clinical and pharmacokinetic study of EPO906 (Epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 20: (Abstr 429).
9. Trepathi R, Gadgeel S, Wozniak A. Phase I clinical trial of BMS-2347550 (epothilone B derivative) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002; 21: (Abstr 407).
10. McDaid HM, Mani S, Shen HJ et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002; 8: 2035-2043.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Ozer H, Armitage JO, Bennett CL et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18: 3558-3585.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
14. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Gelderblom H, Mross K, ten Tije AJ et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 2002; 20: 574-581.
16. Thambi P, Edgerly M, Agrawal M. A phase I clinical trial of BMS-247550 (NSC 71028), an epothilone B derivative, given daily for 3 days on a 21 day cycle in patients with refractory neoplasms. Proc Am Soc Clin Oncol 2003; 22: (Abstr 540).
17. Vansteenkiste J, Breton J, Sandler A. A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003; 22: (Abstr 2519).
18. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 1866-1873.
19. Piro L, Rosen L, Paron M. KOS-862 (Epothiolone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; 22: (Abstr 539).